A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

Rugo Hope S.; Tredan Olivier; Ro Jungsil; Morales Serafin M.; Campone Mario; Musolino Antonino; Afonso Noemia; Ferreira Marta; Park Kyong Hwa; Cortes Javier; Tan Antoinette R.; Blum Joanne L.; Eaton Lamar; Gause Christine K.; Wang Zhen; Im Ellie; Mauro David J.; Jones Mary Beth; Denker Andrew; Baselga Jose

首页> 外文期刊>Breast cancer research and treatment. >A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

【24h】

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

机译：与晚期乳腺癌患者的毒品血清素和20型毒素和20次患者的随机期II试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patients with estrogen receptor (ER)-positive advanced/metastatic breast cancer.

机译：为了评估将人源化单克隆胰岛素生长因子-1受体（IGF-1R）抗体（Dalotuzumab）与哺乳动物（MTOR）抑制剂（Ridaforolimus）加上芳香酶抑制剂（Exemestane）提高雌激素受体（ER）的结果改善了 - 阳性晚期/转移性乳腺癌。

著录项

来源
《Breast cancer research and treatment.》 |2017年第3期|共9页
作者
Rugo Hope S.; Tredan Olivier; Ro Jungsil; Morales Serafin M.; Campone Mario; Musolino Antonino; Afonso Noemia; Ferreira Marta; Park Kyong Hwa; Cortes Javier; Tan Antoinette R.; Blum Joanne L.; Eaton Lamar; Gause Christine K.; Wang Zhen; Im Ellie; Mauro David J.; Jones Mary Beth; Denker Andrew; Baselga Jose;
展开▼
作者单位

UCSF Helen Diller Family Comprehens Canc Ctr 1600 Divisadero St San Francisco CA 94115 USA;

Ctr Leon Berard Lyon France;

Natl Canc Ctr Goyang South Korea;

H Lleida Arnau de Vilanova Lerida Spain;

Inst Cancerol Ouest St Herblain France;

Univ Hosp Parma Parma Italy;

Inst Portugues Oncol Francisco Gentil Oporto Portugal;

Inst Portugues Oncol Francisco Gentil Oporto Portugal;

Korea Univ Med Ctr Seoul South Korea;

Ramon &

Cajal Univ Hosp Madrid Spain;

Rutgers Canc Inst New Jersey New Brunswick NJ USA;

US Oncol Texas Oncol Baylor Sammons Canc Ctr Dallas TX USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Breast cancer; Ridaforolimus; mTOR; Dalotuzumab; IGF1R; Exemestane;

机译：乳腺癌;idaforolimus;mtor;dalotuzumab;IGF1R;EXEMESTANE;

相似文献

外文文献
中文文献
专利

1. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer [J] . Rugo Hope S., Tredan Olivier, Ro Jungsil, Breast cancer research and treatment. . 2017,第3期

机译：与晚期乳腺癌患者的毒品血清素和20型毒素和20次患者的随机期II试验
2. 15 Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer [J] . A.Hasenburg, C.J.H.van de Velde, C.Seynaeve, European Journal of Cancer Supplements . 2010,第3期

机译：15与他莫昔芬相比，依西美坦作为初始疗法为五年，之后为依西美坦，共为五年：TEAM试验是一项针对激素受体阳性早期乳腺癌的绝经后妇女的前瞻性，随机，III期试验
3. First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group [J] . R.Paridaens, P.Therasse, L.Dirix, European Journal of Cancer Supplements . 2004,第3期

机译：一项随机III期试验的初步结果，该试验比较了依西美坦与他莫昔芬作为绝经后转移性乳腺癌（MBC）一线激素疗法（HT）的一线激素治疗— EORTC 10951与依西美坦工作组和NCIC临床试验组合作
4. Towards clinic-friendly solutions for patient trials in breast cancer phase contrast imaging [C] . Sarah J. Lewis, Timur E. Gureyev, Patrycja Baran, International Workshop on Breast Imaging . 2018

机译：迈向临床友好的乳腺癌相衬成像患者试验解决方案
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. A randomized phase II trial of ridaforolimus dalotuzumab and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer [O] . Hope S. Rugo, Olivier Trédan, Jungsil Ro, -1

机译：瑞达福莫司达洛珠单抗和依西美坦与瑞达福莫司和依西美坦在晚期乳腺癌患者中的随机II期试验
7. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial [O] . Burris Howard A, Lebrun Fabienne, Rugo Hope S, 2013

机译：依维莫司联合依西美坦治疗与安慰剂联合依西美坦治疗的晚期乳腺癌患者的健康相关生活质量在3期随机，对照，BOLERO-2试验中

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅